United States - English - NLM (National Library of Medicine)

mylan institutional inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride 10 mg - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematica

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride 10 mg - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematically evaluated in controlle

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride 10 mg - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematically evaluated in controlle

Canada - English - Health Canada

pharmascience inc - thioridazine hydrochloride - tablet - 10mg - thioridazine hydrochloride 10mg - phenothiazines

Canada - English - Health Canada

pharmascience inc - thioridazine hydrochloride - tablet - 100mg - thioridazine hydrochloride 100mg - phenothiazines

Canada - English - Health Canada

pharmascience inc - thioridazine hydrochloride - tablet - 25mg - thioridazine hydrochloride 25mg - phenothiazines

Canada - English - Health Canada

pharmascience inc - thioridazine hydrochloride - solution - 5mg - thioridazine hydrochloride 5mg - phenothiazines

Canada - English - Health Canada

pharmascience inc - thioridazine hydrochloride - solution - 30mg - thioridazine hydrochloride 30mg - phenothiazines

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride 50 mg - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematica

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematica